Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

doi:10.1016/j.semcancer.2017.10.003

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Research output: Contribution to journal › Review article › peer-review

228 Scopus citations

Abstract

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

Original language	English
Pages (from-to)	16-25
Number of pages	10
Journal	Seminars in Cancer Biology
Volume	52
DOIs	https://doi.org/10.1016/j.semcancer.2017.10.003
State	Published - Oct 2018

Bibliographical note

Funding Information:
David Rimm has served as consultant or advisor for: Astra Zeneca, Agendia, Bethyl Labs, Biocept, Bristol-Myers Squibb, Cell Signaling Technology, Merck, OptraScan, Perkin Elmer and Ultivue. David Rimm receives funding from Astra Zeneca, Cepheid, Navigate/Novartis, Gilead Sciences, Pierre Fabre, and Perkin Elmer for research in his laboratory.

Funding Information:
Roberto Salgado was supported by a grant from the Breast Cancer Research Foundation (BCRF) . Federico Rojo was supported by CIBERONC CB/16/12/00481 and PI15/00934 .

Publisher Copyright:
© 2017 The Authors

Keywords

Breast cancer
Ductal carcinoma in situ
Neoadjuvant
Residual cancer burden
Residual disease
Tumor-infiltrating lymphocytes

Access to Document

10.1016/j.semcancer.2017.10.003

Fingerprint

Dive into the research topics of 'Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer'. Together they form a unique fingerprint.

Cite this

on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer (2018). Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 52, 16-25. https://doi.org/10.1016/j.semcancer.2017.10.003

on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. / Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ : A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. In: Seminars in Cancer Biology. 2018 ; Vol. 52. pp. 16-25.

@article{4531db8f82f040edacee112ffc2b226c,

title = "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer",

abstract = "Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.",

keywords = "Breast cancer, Ductal carcinoma in situ, Neoadjuvant, Residual cancer burden, Residual disease, Tumor-infiltrating lymphocytes",

author = "{on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer} and Dieci, {Maria Vittoria} and Nina Radosevic-Robin and Susan Fineberg and {van den Eynden}, Gert and Nils Ternes and Frederique Penault-Llorca and Giancarlo Pruneri and D'Alfonso, {Timothy M.} and Sandra Demaria and Carlos Castaneda and Joselyn Sanchez and Sunil Badve and Stefan Michiels and Veerle Bossuyt and Federico Rojo and Baljit Singh and Torsten Nielsen and Giuseppe Viale and Kim, {Seong Rim} and Stephen Hewitt and Stephan Wienert and Sybille Loibl and David Rimm and Fraser Symmans and Carsten Denkert and Sylvia Adams and Sherene Loi and Roberto Salgado",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors",

year = "2018",

month = oct,

doi = "10.1016/j.semcancer.2017.10.003",

language = "Ingl{\'e}s",

volume = "52",

pages = "16--25",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

publisher = "Academic Press Inc.",

}

on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer 2018, 'Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer', Seminars in Cancer Biology, vol. 52, pp. 16-25. https://doi.org/10.1016/j.semcancer.2017.10.003

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ : A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. / on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

In: Seminars in Cancer Biology, Vol. 52, 10.2018, p. 16-25.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ

T2 - A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

AU - on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

AU - Dieci, Maria Vittoria

AU - Radosevic-Robin, Nina

AU - Fineberg, Susan

AU - van den Eynden, Gert

AU - Ternes, Nils

AU - Penault-Llorca, Frederique

AU - Pruneri, Giancarlo

AU - D'Alfonso, Timothy M.

AU - Demaria, Sandra

AU - Castaneda, Carlos

AU - Sanchez, Joselyn

AU - Badve, Sunil

AU - Michiels, Stefan

AU - Bossuyt, Veerle

AU - Rojo, Federico

AU - Singh, Baljit

AU - Nielsen, Torsten

AU - Viale, Giuseppe

AU - Kim, Seong Rim

AU - Hewitt, Stephen

AU - Wienert, Stephan

AU - Loibl, Sybille

AU - Rimm, David

AU - Symmans, Fraser

AU - Denkert, Carsten

AU - Adams, Sylvia

AU - Loi, Sherene

AU - Salgado, Roberto

PY - 2018/10

Y1 - 2018/10

N2 - Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

AB - Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

KW - Breast cancer

KW - Ductal carcinoma in situ

KW - Neoadjuvant

KW - Residual cancer burden

KW - Residual disease

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85035012871&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2017.10.003

DO - 10.1016/j.semcancer.2017.10.003

M3 - Artículo de revisión

C2 - 29024776

AN - SCOPUS:85035012871

SN - 1044-579X

VL - 52

SP - 16

EP - 25

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

ER -

on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology. 2018 Oct;52:16-25. doi: 10.1016/j.semcancer.2017.10.003

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this